Profile data is unavailable for this security.
About the company
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
- Revenue in AUD (TTM)941.37m
- Net income in AUD15.65m
- Incorporated2017
- Employees234.00
- LocationTelix Pharmaceuticals Ltd55 Flemington Road, North MelbourneMELBOURNE 3051AustraliaAUS
- Phone+61 39093-3855
- Websitehttps://telixpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Suzhou Ribo Life Science Co Ltd | 36.89m | -45.21m | 2.16bn | 404.00 | -- | -- | -- | 58.56 | -1.55 | -1.55 | 1.26 | -0.4093 | -- | -- | -- | -- | -- | -- | -- | -- | 90.90 | -- | -131.95 | -- | 0.9173 | -14.93 | 0.8949 | -- | 324,052.30 | -- | 36.93 | -- | -- | -- |
| Nanjing Leads Biolabs Co Ltd | 0.00 | -58.83m | 2.21bn | 192.00 | -- | 97.39 | -- | -- | -2.01 | -2.01 | 0.00 | 0.6299 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.01 | -- | 0.7407 | -- | -100.00 | -- | 16.85 | -- | -- | -- |
| HitGen Inc | 101.99m | 23.35m | 2.41bn | 483.00 | 104.30 | 8.02 | -- | 23.67 | 0.2824 | 0.2824 | 1.24 | 3.67 | 0.2726 | 6.37 | 4.69 | 1,032,114.00 | 6.18 | 3.06 | 6.87 | 3.36 | 55.23 | 53.55 | 22.67 | 14.48 | 5.12 | 6.59 | 0.1674 | 34.32 | 14.99 | 10.08 | 26.13 | -15.65 | 3.16 | -- |
| InventisBio Co Ltd | 36.93m | -23.79m | 2.60bn | 185.00 | -- | 7.64 | -- | 70.51 | -0.2012 | -0.2012 | 0.3122 | 2.88 | 0.0988 | -- | 1.03 | 975,824.70 | -6.36 | -32.89 | -6.76 | -35.22 | 99.41 | -- | -64.41 | -682.73 | -- | -- | 0.0127 | -- | -9.02 | 25.00 | 15.41 | -- | -3.97 | -- |
| Syngene International Ltd | 580.67m | 54.96m | 2.72bn | 6.53k | 49.79 | -- | 22.01 | 4.69 | 8.72 | 8.72 | 92.16 | -- | -- | -- | -- | 5,694,474.00 | -- | 8.14 | -- | 10.44 | 75.26 | 71.29 | 9.46 | 15.03 | -- | 5.73 | -- | -- | 4.41 | 12.60 | -2.71 | 3.78 | 3.67 | -- |
| Keymed Biosciences Inc | 178.64m | -52.71m | 2.95bn | 1.47k | -- | 4.50 | -- | 16.50 | -1.11 | -1.11 | 3.75 | 12.11 | 0.2068 | 0.3382 | 15.10 | 785,244.60 | -6.10 | -40.63 | -7.27 | -44.60 | 95.19 | -- | -29.48 | -593.20 | 3.74 | -- | 0.2145 | -- | 20.91 | -- | -43.38 | -- | 28.05 | -- |
| Telix Pharmaceuticals Ltd | 941.37m | 15.65m | 2.97bn | 234.00 | 206.25 | 4.98 | 89.40 | 3.15 | 0.0425 | 0.0425 | 2.69 | 1.76 | 0.7909 | 11.01 | 7.28 | -- | 1.31 | -10.99 | 1.82 | -15.18 | 54.00 | 61.79 | 1.66 | -13.10 | 1.22 | -- | 0.4978 | -- | 54.81 | 192.25 | 851.60 | -- | 150.32 | -- |
| Mabwell Shanghai Bioscience Co Ltd | 127.77m | -193.85m | 2.98bn | 1.36k | -- | 19.12 | -- | 23.30 | -2.37 | -2.37 | 1.56 | 1.90 | 0.1384 | 0.3458 | 14.57 | 441,048.00 | -21.06 | -29.90 | -36.19 | -36.18 | 88.72 | 85.56 | -152.14 | -1,188.68 | 0.8093 | -10.82 | 0.7353 | -- | 56.28 | 46.68 | 0.9031 | -- | 12.25 | -- |
| Mesoblast Ltd | 24.26m | -144.11m | 3.07bn | 81.00 | -- | 3.61 | -- | 126.56 | -0.1193 | -0.1193 | 0.0201 | 0.6586 | 0.0237 | -- | 2.25 | 299,550.90 | -14.05 | -13.19 | -15.99 | -14.68 | 70.17 | -132.14 | -593.92 | -957.40 | 1.77 | -4.50 | 0.1766 | -- | 191.39 | -11.76 | -16.13 | -- | -20.16 | -- |
| Ascentage Pharma Group International | 80.00m | -237.42m | 3.21bn | 605.00 | -- | 21.98 | -- | 40.08 | -4.02 | -4.02 | 1.35 | 2.16 | 0.1270 | 3.70 | 0.9505 | 780,234.30 | -37.68 | -30.84 | -60.56 | -41.94 | 90.87 | 94.02 | -296.81 | -252.93 | 1.53 | -- | 0.7174 | -- | 341.77 | 132.25 | 56.20 | -- | -21.49 | -- |
| Sinocelltech Group Ltd | 386.18m | -63.45m | 3.59bn | 2.28k | -- | -- | -- | 9.29 | -0.6964 | -0.6964 | 4.24 | -0.1083 | 0.5458 | 0.4325 | 3.04 | 828,989.10 | -8.37 | -22.66 | -29.60 | -48.25 | 93.51 | 95.52 | -15.33 | -42.96 | 0.5008 | -0.6753 | 1.02 | -- | 33.13 | 294.24 | 127.39 | -- | 23.95 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Challenger Ltd. (Investment Management)as of 21 Jan 2026 | 16.90m | 4.99% |
| State Street Global Advisors, Australia, Ltd.as of 29 Jan 2026 | 14.70m | 4.34% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 9.09m | 2.68% |
| Vanguard Investments Australia Ltd.as of 31 Dec 2025 | 5.73m | 1.69% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 5.05m | 1.49% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 4.13m | 1.22% |
| VanEck Australia Pty Ltd.as of 06 Feb 2026 | 3.57m | 1.05% |
| RBC Global Asset Management (Asia) Ltd.as of 30 Jun 2025 | 2.39m | 0.71% |
| Netwealth Investments Ltd.as of 06 Feb 2025 | 2.01m | 0.59% |
| State Street Global Advisors Trust Co.as of 29 Jan 2026 | 2.01m | 0.59% |
